TY - JOUR
T1 - High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma
AU - Tannir, Nizar M.
AU - Spitzer, Gary
AU - Zander, Axel R.
AU - Jagannath, Sundar
AU - Kanojia, Mahesh
AU - Vellekoop, Lijda
AU - McLaughlin, Peter
AU - Hagemeister, Frederick J.
AU - Dicke, Karel A.
N1 - Funding Information:
Accepted 23 February 1983. *Supported in part by Grants CA 14528 and CA 28153 from the National Cancer Institute. $Dr. Spitzer is a Scholar of the Leukemia Society of America.
PY - 1983/8
Y1 - 1983/8
N2 - Eight adult patients with refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with high-dose combination chemotherapy (cyclophosphamide, BCNU and VP-16) or with cyclophosphamide and fractioned whole-body irradiation (TBI), followed by bone marrow transplant (BMT). Six patients received autologous and two patients allogeneic BMT. Five patients achieved complete remissions, and three of them (two with undifferentiated lymphoma, one with lymphoblastic lymphoma) are alive and free of disease 4-18+ months after BMT. The other two complete responders died of opportunistic infections 2 and 5 months, respectively, after BMT. One patient with HD achieved partial remission and is alive 18+ months after BMT. Two patients were considered failures: one developed leptomeningeal disease 24 days after BMT, and the other dies of progressive lymphoma 7 months after BMT. Engraftment and prompt hematologic recovery occurred in all patients. The major toxicity included two fatal infections and one case of diffuse idiopathic interstitial pneumonitis. High-dose chemotherapy with or without TBI followed by BMT appears to produce a high response rate and, although associated with toxicity, it demonstrates the potential for salvaging patients with refractory lymphoma who otherwise would have a dismal prognosis.
AB - Eight adult patients with refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with high-dose combination chemotherapy (cyclophosphamide, BCNU and VP-16) or with cyclophosphamide and fractioned whole-body irradiation (TBI), followed by bone marrow transplant (BMT). Six patients received autologous and two patients allogeneic BMT. Five patients achieved complete remissions, and three of them (two with undifferentiated lymphoma, one with lymphoblastic lymphoma) are alive and free of disease 4-18+ months after BMT. The other two complete responders died of opportunistic infections 2 and 5 months, respectively, after BMT. One patient with HD achieved partial remission and is alive 18+ months after BMT. Two patients were considered failures: one developed leptomeningeal disease 24 days after BMT, and the other dies of progressive lymphoma 7 months after BMT. Engraftment and prompt hematologic recovery occurred in all patients. The major toxicity included two fatal infections and one case of diffuse idiopathic interstitial pneumonitis. High-dose chemotherapy with or without TBI followed by BMT appears to produce a high response rate and, although associated with toxicity, it demonstrates the potential for salvaging patients with refractory lymphoma who otherwise would have a dismal prognosis.
UR - http://www.scopus.com/inward/record.url?scp=0020520548&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(83)90033-0
DO - 10.1016/0277-5379(83)90033-0
M3 - Article
C2 - 6352279
AN - SCOPUS:0020520548
SN - 0277-5379
VL - 19
SP - 1091
EP - 1096
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 8
ER -